Effects of Different Doses and Duration of Iron Supplementation on Curing Iron Deficiency Anemia: an Experimental Study

2014 ◽  
Vol 162 (1-3) ◽  
pp. 242-251 ◽  
Author(s):  
Juan Ma ◽  
Xiaosha Wen ◽  
Fengfeng Mo ◽  
Xiaoli Wang ◽  
Zhilei Shen ◽  
...  
Keyword(s):  
Experimental Study ◽  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Iron Supplementation ◽  
Deficiency Anemia ◽  
Different Doses

scholarly journals Association of Iron Supplementation Programs with Iron-Deficiency Anemia Outcomes among Children in Brazil

Nutrients ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 1524
Author(s):  
Carolina Thalya da Silva Paulino ◽  
Marislei Nishijima ◽  
Flavia Mori Sarti
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Fixed Effects ◽  
Iron Supplementation ◽  
Deficiency Anemia ◽  
Federal Programs ◽  
Government Programs ◽  
Lengths Of Stay ◽  
Social Inequities ◽  
High Prevalence

Anemia remains a condition with high prevalence in populations worldwide, and the prevalence of anemia among children under five years old in Brazil is approximately 40%, being higher in communities marked by social inequities. Diverse government programs during recent decades targeted iron-deficiency anemia, considering its impacts throughout the lifetime. The objective of this study was to investigate the effects of two government iron supplementation programs on health outcomes related to iron-deficiency anemia among children up to 4 years old in Brazilian municipalities. A longitudinal panel encompassing data from 5570 municipalities from 1998 to 2019 was investigated using a difference-in-differences framework with multiple interventions and distinct times of adhesion, and fixed-effects models were estimated to control for invariant municipal characteristics throughout the period in order to ensure comparability. The results indicate significant effects of the federal programs in reducing hospitalizations and lengths of stay due to iron-deficiency anemia, especially in non-poor municipalities. There was complementarity in the effects of the programs; however, neither of the programs influenced mortality rates. Thus, it is important to consider possible improvements in the operationalization of the programs, in order to achieve better results in the reduction of severe iron-deficiency anemia among children up to 4 years old.

Role of Iron Supplementation in Reducing Severity of Depression: A Review

2020 ◽  
pp. 67-76
Author(s):  
OJS Admin
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Iron Supplementation ◽  
Reproductive Age ◽  
Deficiency Anemia ◽  
Essential Nutrient ◽  
Severity Of Depression ◽  
The Impact ◽  
Clinical Problems

Depression is a public health disorder, ranking third after respiratory and cardiac diseases. There were many evidences that iron deficiency anemia (IDA) is one of the foremost causes regarding nutritional pointof view for depression. We reviewed these evidences that IDAlinking to depression. We identified seventeen studies in four databases including randomized-controlled trials (RCTs) and observational studies assessing the impact of IDAand iron supplementation on the risk of depression. We extracted data on the basis of sample size, geographical region, measures of depression, hemoglobin, iron levels and intake of iron supplementation and critically appraised the results from the studies. Eleven out of sixty one studies were experimental, which indicated that dietary supplementation particularly iron supplementation had an association (r − 0.19 to −0.43 and ORs 1.70–4.64) with severity of depression. Evidences showed that women of reproductive age were more vulnerable to iron deficiency anemia than other population. Low ferritin and low hemoglobin level were associated with severity of depression. Iron is an essential nutrient for all living creatures, as a cofactor of various enzymes and plays significant role in environmental stimulant for the articulation of numerous virulence factors. Many clinical problems are caused by iron deficiency. Therefore, this review intended to highlight the important role of iron supplementation in reducing the severity of depression.

Characterization of the population with severe iron deficiency anemia at risk of requiring intravenous iron supplementation

2018 ◽  
Vol 224 ◽  
pp. 41-44 ◽  
Author(s):  
Josep Estadella ◽  
Laura Villamarín ◽  
Anna Feliu ◽  
Josep Perelló ◽  
Joaquim Calaf
Keyword(s):  
At Risk ◽  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Iron Supplementation ◽  
Intravenous Iron ◽  
Deficiency Anemia ◽  
Intravenous Iron Supplementation

scholarly journals Iron supplementation in goitrous, iron-deficient children improves their response to oral iodized oil

2000 ◽  
pp. 217-223 ◽  
Author(s):  
M Zimmermann ◽  
P Adou ◽  
T Torresani ◽  
C Zeder ◽  
R Hurrell
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Iron Supplementation ◽  
Thyroid Volume ◽  
Oral Iron ◽  
Deficiency Anemia ◽  
Urinary Iodine Concentration ◽  
Iodized Oil ◽  
Iron Deficient ◽  
Group 2

OBJECTIVE: In developing countries, many children are at high risk for both goiter and iron-deficiency anemia. Because iron deficiency may impair thyroid metabolism, the aim of this study was to determine if iron supplementation improves the response to oral iodine in goitrous, iron-deficient anemic children. DESIGN: A trial of oral iodized oil followed by oral iron supplementation in an area of endemic goiter in the western Ivory Coast. METHODS: Goitrous, iodine-deficient children (aged 6-12 years; n=109) were divided into two groups: Group 1 consisted of goitrous children who were not anemic; Group 2 consisted of goitrous children who were iron-deficient anemic. Both groups were given 200mg oral iodine as iodized oil. Thyroid gland volume using ultrasound, urinary iodine concentration (UI), serum thyroxine (T(4)) and whole blood TSH were measured at baseline, and at 1, 5, 10, 15 and 30 weeks post intervention. Beginning at 30 weeks, the anemic group was given 60mg oral iron as ferrous sulfate four times/week for 12 weeks. At 50 and 65 weeks after oral iodine (8 and 23 weeks after completing iron supplementation), UI, TSH, T(4) and thyroid volume were remeasured. RESULTS: The prevalence of goiter at 30 weeks after oral iodine in Groups 1 and 2 was 12% and 64% respectively. Mean percent change in thyroid volume compared with baseline at 30 weeks in Groups 1 and 2 was -45.1% and -21.8% respectively (P<0.001 between groups). After iron supplementation in Group 2, there was a further decrease in mean thyroid volume from baseline in the anemic children (-34.8% and -38.4% at 50 and 65 weeks) and goiter prevalence fell to 31% and 20% at 50 and 65 weeks. CONCLUSION: Iron supplementation may improve the efficacy of oral iodized oil in goitrous children with iron-deficiency anemia.

scholarly journals Ferric Gluconate Complex in Elderly Hospital Inpatients without Terminal Kidney Failure

2018 ◽  
Vol 71 (3) ◽  
Author(s):  
Patrick Viet-Quoc Nguyen ◽  
Judith Latour
Keyword(s):  
Iron Deficiency ◽  
Elderly Patients ◽  
Iron Deficiency Anemia ◽  
Kidney Failure ◽  
Iron Supplementation ◽  
Adverse Reactions ◽  
Deficiency Anemia ◽  
Patients Âgés ◽  
Parenteral Iron ◽  
Taux D’Hémoglobine

<p><strong>ABSTRACT</strong></p><p><strong>Background: </strong>Anemia is a common health issue for elderly patients. For patients with iron deficiency who cannot tolerate iron supplementation by the oral route, the parenteral route may be used. Options for parenteral iron supplementation include ferric gluconate complex (FGC).</p><p><strong>Objectives: </strong>To evaluate the safety of FGC in elderly patients without terminal kidney failure and to assess its efficacy in treating iron-deficiency anemia.</p><p><strong>Methods: </strong>An observational chart review was conducted at a tertiary care university health centre. Patients included in the study were 65 years of age or older, had received at least 1 dose of FGC between January 1, 2014, and December 31, 2015, and had a hemoglobin count of less than 130 g/L (men) or less than 120 g/L (women) at baseline. For each patient, the observation period began when the first dose of FGC was administered and ended 60 days after the last dose. The main safety outcome (occurrence of any adverse reaction) was evaluated for every patient, with the efficacy analysis being limited to patients with a diagnosis of iron deficiency anemia.</p><p><strong>Results: </strong>A total of 144 patients were included in the study, of whom 76 had iron-deficiency anemia. No serious, life-threatening adverse reactions were reported. The most commonly reported adverse reactions were nausea and vomiting. The mean increase in hemoglobin count was 13.5 g/L, a statistically significant change from baseline.</p><p><strong>Conclusions: </strong>These results show that FGC is safe for use in elderly patients, with very few mild adverse reactions. Use of FGC led to increased hemoglobin count within 60 days. Of the 3 options for parenteral iron supplementation available in Canada, iron sucrose has not been studied in elderly patients, and iron dextran has a higher incidence of anaphylaxis, whereas FGC appears to be a safe alternative for patients with intolerance to oral iron.</p><p><strong>RÉSUMÉ</strong></p><p><strong>Contexte : </strong>L’anémie est un problème de santé courant chez les patients âgés. Les patients qui présentent une carence en fer et une intolérance à la prise de suppléments de fer par la voie orale peuvent être traités par voie parentérale. Le complexe de gluconate ferrique de sodium (CGFS) représente l’une des options d’apport complémentaire en fer par voie parentérale.</p><p><strong>Objectifs : </strong>Évaluer l’innocuité du CGFS chez le patient âgé qui n’est pas atteint d’insuffisance rénale terminale et évaluer son efficacité dans le traitement de l’anémie ferriprive.</p><p><strong>Méthodes : </strong>Une analyse observationnelle a été menée au moyen des dossiers médicaux dans un établissement de santé universitaire de soins tertiaires. Les patients dont le dossier médical a été retenu pour l’analyse étaient âgés de 65 ans ou plus, avaient reçu au moins une dose de CGFS entre le 1er janvier 2014 et le 31 décembre 2015 et présentaient initialement un taux d’hémoglobine de moins de 130 g/L (hommes) ou de moins de 120 g/L (femmes). Pour chaque patient, la période d’observation s’étendait du moment où la première dose de CGFS avait été administrée au soixantième jour suivant la dernière dose. Le principal paramètre d’évaluation de l’innocuité (survenue de toute reaction indésirable) faisait l’objet d’une évaluation pour chaque patient. L’analyse de l’efficacité se limitait aux patients ayant reçu un diagnostic d’anémie ferriprive.</p><p><strong>Résultats : </strong>Au total, 144 patients ont été admis à l’étude et, parmi eux, 76 présentaient une anémie ferriprive. Aucune réaction indésirable grave menaçant la vie du patient n’a été notée. Les réactions indésirables les plus souvent signalées étaient des nausées et des vomissements. L’augmentation moyenne des taux d’hémoglobine était de 13,5 g/L, un changement statistiquement significatif comparé à la valeur de départ.</p><p><strong>Conclusions : </strong>Les résultats montrent que le CGFS est sécuritaire pour le patient âgé et qu’il ne provoque que très peu de réactions indésirables légères. L’emploi du CGFS a produit une augmentation des taux d’hémoglobine en moins de 60 jours. Parmi les 3 options d’apport complémentaire en fer pris par voie parentérale disponibles au Canada, le fer-saccharose n’a pas été étudié auprès de patients âgés et le fer-dextran est associé à une plus grande incidence de cas d’anaphylaxie; or, le CGFS semble être une solution sécuritaire pour les patients qui présentent une intolérance au fer administré par voie orale.</p>

scholarly journals Psychiatric disorders risk in patients with iron deficiency anemia and association with iron supplementation medications: a nationwide database analysis

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Herng-Sheng Lee ◽  
Hsin-Hao Chao ◽  
Wan-Ting Huang ◽  
Solomon Chih-Cheng Chen ◽  
Hsin-Yi Yang
Keyword(s):  
Iron Deficiency ◽  
Psychiatric Disorders ◽  
Iron Deficiency Anemia ◽  
Iron Supplementation ◽  
Deficiency Anemia ◽  
Database Analysis ◽  
Nationwide Database

scholarly journals Iron Supplementation in Suckling Piglets: How to Correct Iron Deficiency Anemia without Affecting Plasma Hepcidin Levels

PLoS ONE ◽  
2013 ◽  
Vol 8 (5) ◽  
pp. e64022 ◽  
Author(s):  
Rafał R. Starzyński ◽  
Coby M. M. Laarakkers ◽  
Harold Tjalsma ◽  
Dorine W. Swinkels ◽  
Marek Pieszka ◽  
...  
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Iron Supplementation ◽  
Deficiency Anemia ◽  
Suckling Piglets
Sign in / Sign up

Export Citation Format

Share Document